Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Journal

Related Articles

See more

Details

  • CRID
    1370286443560681991
  • Data Source
    • Crossref
Back to top